APA (7th ed.) Citation

Ding, Y., Wang, C., Shu, Y., Wang, J., & Zhang, Q. (2025). Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial. Journal of Pharmaceutical Policy & Practice, 18(1), 1. https://doi.org/10.1080/20523211.2025.2464781

Chicago Style (17th ed.) Citation

Ding, Yiling, Chunping Wang, Yamin Shu, Jinglin Wang, and Qilin Zhang. "Cost-effectiveness Analysis of a First-line Treatment with Cadonilimab Plus Platinum-based Chemotherapy with or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer in China: COMPASSION-16 Trial." Journal of Pharmaceutical Policy & Practice 18, no. 1 (2025): 1. https://doi.org/10.1080/20523211.2025.2464781.

MLA (9th ed.) Citation

Ding, Yiling, et al. "Cost-effectiveness Analysis of a First-line Treatment with Cadonilimab Plus Platinum-based Chemotherapy with or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer in China: COMPASSION-16 Trial." Journal of Pharmaceutical Policy & Practice, vol. 18, no. 1, 2025, p. 1, https://doi.org/10.1080/20523211.2025.2464781.